Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ABHD2, a member of the hydrolase protein family, has hydrolase activity and is involved in the regulation of lipid metabolism. ABHD2 gene is expressed in alveolar type II epithelial cells and bronchial smooth muscle cells, and ABHD2 knockout mice can naturally develop emphysema. Clinical studies have found that mutations in the rs12442260 gene in the human ABHD2 gene increase the risk of developing chronic obstructive pulmonary disease (COPD). Therefore, ABHD2 plays an important role in the occurrence and development of emphysema and COPD. Screening for ABHD2 susceptibility genes is expected to be a target for early detection, early prevention, and treatment of people with the predisposition to COPD.
ABHD2 Features
ABHD2 is a hydrolase protein expressed in humans. In 2002, Edgar and Polak cloned three cDNA sequences encoding hydrolase proteins from mouse lung cDNA libraries and named them lung hydrolase (Labh), now known as hydrolase domains 1, 2 and 3. Human ABHD2, the lung α/β hydrolase 2, consists of 425 residual proteins. The expression of ABHD2 is expressed in various tissues in mice, especially in the lung, adrenal gland and brain. ABHD2 is a unidirectional type II membrane protein with hydratase catalytic activity and is involved in the migration of vascular smooth muscle cells. ABHD2 is first expressed in endothelial cells and then transferred to smooth muscle cells to inhibit cell migration and intimal hyperplasia. The ABHD2 gene is expressed in lung type II cells and is involved in alveolar phospholipid metabolism.
The ABHD2 knockout mice constructed by gene capture technology have decreased type II cells, decreased phosphatidylcholine content on the alveolar surface, and increased pulmonary macrophage infiltration, and are closely related to age. Reimann et al. found that spontaneous formation of emphysema in ABHD2 knockout mice was due to increased macrophage infiltration on the alveolar surface, protease/antiprotease imbalance, and excessive expression of proinflammatory cytokines. In unstable angina, the expression of ABHD2 is increased. It regulates lipid metabolism, causes plaque rupture, and promotes the progression of atherosclerotic lesions, which is a key factor in the progression of unstable angina. Atherosclerosis is a chronic inflammatory response caused by a variety of factors, of which the role of smooth muscle cells is particularly important.
ABHD2 gene deletion promotes vascular smooth muscle cell migration and promotes neointimal hyperplasia. Studies have shown that the number of alveolar type II epithelial cells in ABHD2 gene-deficient mice is reduced, the phosphatidylcholine (PC) content in bronchoalveolar lavage fluid (BALF) is decreased, and the PC content in lung homogenate is not significantly changed. This suggests that the decrease in PC content in BALF is due to a decrease in PC secretion levels or a disturbance in phospholipid metabolism on the alveolar surface, independent of a decrease in the number of alveolar epithelial cells. A clinical histological analysis of colorectal cancer gene expression data suggests that the ABHD2 gene may be involved in the development of colorectal cancer. Insertion of retroviruses in mice drives high expression of the ABHD2 gene in expression analysis of genes involved in the progression of brain tumors (gliomas). Related studies in the spread of human hepatitis B virus have shown that the ABHD2 gene blocks the spread of human hepatitis B virus. Thus, ABHD2 plays an important role in the occurrence and development of various diseases.
Figure 1. The function of ABHD2. (Robert Sanders. 2016).
ABHD2 and Emphysema
The pathological changes of emphysema are mainly the excessive expansion of the alveoli and the decrease of its elasticity. Related studies have shown that ABHD2 has hydrolase activity and is a member of the hydrolase protein family. The hydrolase protein family is screened from emphysema tissue genes. The team used the replaceable gene capture technology to find that the ABHD2 gene is expressed in smooth muscle cells, hepatic portal veins, alveolar cells, and bronchial smooth muscle cells. The smooth muscle cell migration and the intimal hyperplasia of ABHD2 knockout homozygous mice. By constructing ABHD2 gene-trapped mice (ABHD2Gt/Gt), compared with wild-type mice (ABHD2+/+), it was found that the 12-month-old ABHD2 gene trapped mice had disordered alveolar surfactant metabolism and increased macrophage infiltration. Moreover, the inflammatory factors of the trachea are excessively secreted, the number of alveolar type II epithelial cells is decreased, abnormal apoptosis, alveolar structure destruction, and spontaneous formation of an age-related emphysema phenotype. This process is similar to the occurrence of human emphysema. Consistent with later related studies, ABHD2 is a down-regulated gene of emphysema.
ABHD2 and COPD
The main pathophysiological changes in COPD are pulmonary ventilation dysfunction caused by persistent airflow limitation. The combination of ventilation/blood flow imbalance and diffusion disorder leads to obstacles in ventilation function. The amino acid sequence encoded by the mouse ABHD2 gene is 99% identical to the human homologous gene product. It can be speculated that mouse ABHD2 should have a similar function to human ABHD2. Liu et al. analyzed the association of single-nucleotide polymorphisms (SNPs) in humans with the risk of COPD in the Han population and found that the rs12442260 polymorphism of ABHD2 gene may increase the risk of COPD. This study extracted genomic DNA from patients with COPD and normal controls, screened for SNPs in the ABHD2 gene, and compared their frequency with their smoking status and lung function. The results showed that the CT/CC genotype of the ABHD2 gene at rs12442260 increased the risk of COPD by 83%, especially in former smokers. This finding further supports the hypothesis that the ABHD2 gene plays an important role in the development of COPD. Rs12442260 is located in the fifth intron of the human ABHD2 gene, 489 bp upstream of the sixth exon.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.